Why is Alivus Life falling/rising?

As of 02-Sep, Alivus Life Sciences Ltd is experiencing a decline in its stock price, currently at 933.00, reflecting a decrease of 5.7 points or 0.61%. The stock has underperformed its sector by 0.54% today and has been on a consecutive downward trend for the last five days, resulting in a total drop of 3.75% during this period. Additionally, the stock is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages. Over the past year, Alivus has generated a return of -12.31%, despite a 10.9% increase in profits, indicating a disconnect between stock performance and profitability. The company has a high return on equity (ROE) of 25.32% and a low debt-to-equity ratio, but it is trading at a premium compared to its peers, which may deter some investors.
In the broader market context, Alivus's short-term performance has been notably weaker than the benchmark Sensex, which has declined only 0.78% over the past week compared to Alivus's 1.73% drop. The stock's liquidity is adequate, but a significant decrease in delivery volume by 71.98% against the 5-day average suggests diminishing investor interest. Furthermore, the company's long-term growth prospects appear poor, with net sales growing at an annual rate of only 4.49% over the last five years. These factors collectively contribute to the stock's recent decline, as investors may be cautious given the lack of strong growth indicators and the stock's underperformance relative to the market.